- Home
- AGIO vs CLMT Comparison
AGIO vs CLMT Comparison
Compare AGIO & CLMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- CLMT
- Stock Information
- Founded
- AGIO 2007
- CLMT 1916
- Country
- AGIO United States
- CLMT United States
- Employees
- AGIO N/A
- CLMT N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- CLMT Oil & Gas Production
- Sector
- AGIO Health Care
- CLMT Energy
- Exchange
- AGIO Nasdaq
- CLMT Nasdaq
- Market Cap
- AGIO 1.4B
- CLMT 1.2B
- IPO Year
- AGIO 2013
- CLMT 2006
- Fundamental
- Price
- AGIO $38.80
- CLMT $15.95
- Analyst Decision
- AGIO Buy
- CLMT Strong Buy
- Analyst Count
- AGIO 6
- CLMT 6
- Target Price
- AGIO $57.40
- CLMT $20.38
- AVG Volume (30 Days)
- AGIO 976.6K
- CLMT 896.8K
- Earning Date
- AGIO 07-31-2025
- CLMT 08-08-2025
- Dividend Yield
- AGIO N/A
- CLMT N/A
- EPS Growth
- AGIO N/A
- CLMT N/A
- EPS
- AGIO 11.13
- CLMT N/A
- Revenue
- AGIO $40,875,000.00
- CLMT $4,070,400,000.00
- Revenue This Year
- AGIO $18.94
- CLMT $1.02
- Revenue Next Year
- AGIO $201.70
- CLMT $2.01
- P/E Ratio
- AGIO $3.49
- CLMT N/A
- Revenue Growth
- AGIO 30.57
- CLMT N/A
- 52 Week Low
- AGIO $23.42
- CLMT $7.68
- 52 Week High
- AGIO $62.58
- CLMT $25.29
- Technical
- Relative Strength Index (RSI)
- AGIO 58.69
- CLMT 58.76
- Support Level
- AGIO $34.71
- CLMT $12.94
- Resistance Level
- AGIO $37.73
- CLMT $14.49
- Average True Range (ATR)
- AGIO 1.50
- CLMT 0.90
- MACD
- AGIO 0.15
- CLMT 0.10
- Stochastic Oscillator
- AGIO 82.21
- CLMT 88.53
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About CLMT Calumet Specialty Products Partners L.P. Common Units
Calumet Inc is a producer of specialty products, including base oils, specialty oils, solvents, esters, and waxes, as well as a variety of fuel and fuel-related products, including asphalt and heavy fuel oils. The company manufactures, formulates, and markets a variety of specialty branded products to customers in various consumer-facing and industrial markets. Its segments include: Specialty Products and Solutions; Montana/Renewables; Performance Brands; and Corporate. The company generates maximum revenue from Fuels, asphalt and other by-products.